JP2020504766A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504766A5 JP2020504766A5 JP2019554486A JP2019554486A JP2020504766A5 JP 2020504766 A5 JP2020504766 A5 JP 2020504766A5 JP 2019554486 A JP2019554486 A JP 2019554486A JP 2019554486 A JP2019554486 A JP 2019554486A JP 2020504766 A5 JP2020504766 A5 JP 2020504766A5
- Authority
- JP
- Japan
- Prior art keywords
- benzyl
- methyl
- oxy
- chloro
- oxazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 52
- -1 cyano, formyl Chemical group 0.000 claims 49
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims 23
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 4
- 125000005605 benzo group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Chemical group 0.000 claims 2
- 239000001301 oxygen Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- RFFNGZCDGSQVPC-AOYODBLASA-N (2S)-1-[[4-[[3-[2-(3-amino-1-bicyclo[1.1.1]pentanyl)-1,3-benzoxazol-5-yl]-2-methylphenyl]methoxy]-5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound Cc1c(COc2cc(OCc3cncc(c3)C#N)c(CN3CCCC[C@H]3C(O)=O)cc2Cl)cccc1-c1ccc2oc(nc2c1)C12CC(N)(C1)C2 RFFNGZCDGSQVPC-AOYODBLASA-N 0.000 claims 1
- APDFJOANMZAJSH-XHNMUALFSA-N (2S)-1-[[4-[[3-[2-(8-azabicyclo[3.2.1]octan-3-yl)-1,3-benzoxazol-5-yl]-2-methylphenyl]methoxy]-5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound C12CC(CC(CC1)N2)C=1OC2=C(N=1)C=C(C=C2)C=1C(=C(COC2=CC(=C(CN3[C@@H](CCCC3)C(=O)O)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C APDFJOANMZAJSH-XHNMUALFSA-N 0.000 claims 1
- LCPBGYNRWJBHPD-BHVANESWSA-N (2S)-1-[[4-[[3-[2-[1-(carboxymethyl)piperidin-4-yl]-1,3-benzoxazol-5-yl]-2-methylphenyl]methoxy]-5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound C(=O)(O)CN1CCC(CC1)C=1OC2=C(N=1)C=C(C=C2)C=1C(=C(COC2=CC(=C(CN3[C@@H](CCCC3)C(=O)O)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C LCPBGYNRWJBHPD-BHVANESWSA-N 0.000 claims 1
- SZLIUHMLWHFJOR-VCWBJQSESA-N (2S)-1-[[4-[[3-[3-(8-azabicyclo[3.2.1]oct-2-en-3-yl)quinoxalin-6-yl]-2-methylphenyl]methoxy]-5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound C12C=C(CC(CC1)N2)C=1C=NC2=CC=C(C=C2N=1)C=1C(=C(COC2=CC(=C(CN3[C@@H](CCCC3)C(=O)O)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C SZLIUHMLWHFJOR-VCWBJQSESA-N 0.000 claims 1
- IOIOJFKMYGBHGF-LHEWISCISA-N (2S)-1-[[5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]-4-[[2-methyl-3-[2-(1-propan-2-ylpiperidin-4-yl)-1,3-benzoxazol-5-yl]phenyl]methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=CC2=C(N=C(O2)C2CCN(CC2)C(C)C)C=1)C IOIOJFKMYGBHGF-LHEWISCISA-N 0.000 claims 1
- YZZZQJDDXDSCSF-XHNMUALFSA-N (2S)-1-[[5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]-4-[[2-methyl-3-[2-(8-oxabicyclo[3.2.1]octan-3-yl)-1,3-benzoxazol-5-yl]phenyl]methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound C12CC(CC(CC1)O2)C=1OC2=C(N=1)C=C(C=C2)C=1C(=C(COC2=CC(=C(CN3[C@@H](CCCC3)C(=O)O)C=C2Cl)OCC=2C=NC=C(C=2)C#N)C=CC=1)C YZZZQJDDXDSCSF-XHNMUALFSA-N 0.000 claims 1
- JTNPCCAJVWEZHN-CNZQJSNXSA-N (2S)-1-[[5-chloro-2-[(5-cyanopyridin-3-yl)methoxy]-4-[[3-[2-(4-methoxycarbonylcyclohexyl)-1,3-benzoxazol-5-yl]-2-methylphenyl]methoxy]phenyl]methyl]piperidine-2-carboxylic acid Chemical compound ClC=1C(=CC(=C(CN2[C@@H](CCCC2)C(=O)O)C=1)OCC=1C=NC=C(C=1)C#N)OCC1=C(C(=CC=C1)C=1C=CC2=C(N=C(O2)C2CCC(CC2)C(=O)OC)C=1)C JTNPCCAJVWEZHN-CNZQJSNXSA-N 0.000 claims 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- AQDIORAYAFJBDK-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)-1,3-benzoxazole Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2O1 AQDIORAYAFJBDK-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- GUYHISWJRSVFST-UHFFFAOYSA-N 5-[[4-chloro-2-[[(1,3-dihydroxy-2-methylpropan-2-yl)-methylamino]methyl]-5-[[2-methyl-3-[2-(4-methylpiperazin-1-yl)-1,3-benzoxazol-5-yl]phenyl]methoxy]phenoxy]methyl]pyridine-3-carbonitrile Chemical compound ClC1=CC(=C(OCC=2C=NC=C(C#N)C=2)C=C1OCC1=C(C(=CC=C1)C=1C=CC2=C(N=C(O2)N2CCN(CC2)C)C=1)C)CN(C)C(CO)(CO)C GUYHISWJRSVFST-UHFFFAOYSA-N 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436674P | 2016-12-20 | 2016-12-20 | |
| US62/436,674 | 2016-12-20 | ||
| PCT/US2017/067198 WO2018118848A1 (en) | 2016-12-20 | 2017-12-19 | Compounds useful as immunomodulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504766A JP2020504766A (ja) | 2020-02-13 |
| JP2020504766A5 true JP2020504766A5 (enExample) | 2021-01-28 |
| JP7106572B2 JP7106572B2 (ja) | 2022-07-26 |
Family
ID=60972418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554486A Active JP7106572B2 (ja) | 2016-12-20 | 2017-12-19 | 免疫調節剤として有用な化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10882844B2 (enExample) |
| EP (1) | EP3558970B1 (enExample) |
| JP (1) | JP7106572B2 (enExample) |
| KR (1) | KR102599339B1 (enExample) |
| CN (1) | CN110072860B (enExample) |
| ES (1) | ES2891528T3 (enExample) |
| WO (1) | WO2018118848A1 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3474845B1 (en) | 2016-06-27 | 2024-03-20 | ChemoCentryx, Inc. | Immunomodulator compounds |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| JP7150745B2 (ja) | 2017-03-27 | 2022-10-11 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤としての置換イソキノリン誘導体 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
| US10919852B2 (en) | 2017-07-28 | 2021-02-16 | Chemocentryx, Inc. | Immunomodulator compounds |
| KR102670486B1 (ko) | 2017-08-08 | 2024-05-28 | 케모센트릭스, 인크. | 마크로사이클릭 면역조절제 |
| JP7037667B2 (ja) | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US11414418B2 (en) | 2018-01-23 | 2022-08-16 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019165043A2 (en) | 2018-02-22 | 2019-08-29 | Chemocentryx, Inc. | Indane-amines as pd-l1 antagonists |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| US11578054B2 (en) | 2018-03-01 | 2023-02-14 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US12083118B2 (en) | 2018-03-29 | 2024-09-10 | Arbutus Biopharma Corporation | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| TWI869058B (zh) | 2018-07-27 | 2025-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| JP7453963B2 (ja) * | 2018-09-13 | 2024-03-21 | 貝達薬業股▲ふん▼有限公司 | 免疫調節剤、並びにその組成物及び調製方法 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| AU2019373702A1 (en) | 2018-11-02 | 2021-06-24 | Shanghai Maxinovel Pharmaceuticals Co., Ltd. | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof |
| CN109456284A (zh) * | 2018-11-13 | 2019-03-12 | 南方医科大学 | 一种含取代联苯的查尔酮及其应用 |
| TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| CN109734705B (zh) * | 2019-02-01 | 2021-09-28 | 浙江工业大学 | 一种经脱卤烷基化制备n-杂环芳烃衍生物的方法 |
| WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CN113574063B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| WO2020198676A1 (en) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| KR20210146348A (ko) | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| BR112021022659A2 (pt) | 2019-05-15 | 2022-03-29 | Chemocentryx Inc | Compostos triarílicos para o tratamento de doenças pd-l1 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| JP2022534982A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| KR102841588B1 (ko) | 2019-06-20 | 2025-08-01 | 케모센트릭스, 인크. | Pd-l1 질환의 치료를 위한 화합물 |
| KR102890201B1 (ko) | 2019-07-10 | 2025-11-24 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| WO2021055994A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| ES3068390T3 (en) | 2019-10-16 | 2026-05-29 | Chemocentryx Inc | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
| AU2020368392B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| EP4054723A1 (en) | 2019-11-08 | 2022-09-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| KR102987126B1 (ko) | 2020-03-20 | 2026-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| CN114075123B (zh) | 2020-08-11 | 2023-06-06 | 中国人民解放军军事科学院军事医学研究院 | 苄胺类衍生物及其制备方法与用途 |
| MX2023002332A (es) | 2020-08-28 | 2023-03-21 | Bristol Myers Squibb Co | Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular. |
| IL300916A (en) | 2020-08-31 | 2023-04-01 | Bristol Myers Squibb Co | Cell localization signature and immunotherapy |
| WO2022052926A1 (zh) | 2020-09-09 | 2022-03-17 | 广州再极医药科技有限公司 | 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用 |
| US11833209B2 (en) | 2020-09-11 | 2023-12-05 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| CN117858719A (zh) | 2021-03-29 | 2024-04-09 | 朱诺治疗学股份有限公司 | 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法 |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| CN113200976B (zh) * | 2021-05-17 | 2023-03-07 | 华东理工大学 | 3-芳基氮杂双环衍生物及其制备和杀线虫应用 |
| TWI861509B (zh) | 2021-06-11 | 2024-11-11 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗體藥物接合物之組合 |
| JP7900421B2 (ja) | 2021-06-11 | 2026-08-04 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| AU2023213937A1 (en) | 2022-01-26 | 2024-07-18 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
| JP7851417B2 (ja) | 2022-04-08 | 2026-04-24 | ブリストル－マイヤーズ スクイブ カンパニー | 三次リンパ組織様構造の機械学習識別、分類、及び定量化 |
| KR20250123912A (ko) | 2022-12-21 | 2025-08-18 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 병용 요법 |
| CN118619942A (zh) * | 2023-03-07 | 2024-09-10 | 上海再极医药科技有限公司 | 一种含苯环类化合物及其制备方法和应用 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| TW202608468A (zh) | 2024-05-13 | 2026-03-01 | 美商基利科學股份有限公司 | 組合療法 |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| JP2008515992A (ja) | 2004-10-13 | 2008-05-15 | ピーティーシー セラピューティクス，インコーポレーテッド | 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用 |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| TW200902008A (en) | 2007-05-10 | 2009-01-16 | Smithkline Beecham Corp | Quinoxaline derivatives as PI3 kinase inhibitors |
| WO2011026579A1 (en) | 2009-09-04 | 2011-03-10 | Bayer Schering Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| MX2016002544A (es) | 2013-09-04 | 2016-06-17 | Squibb Bristol Myers Co | Compuestos utiles como inmunomoduladores. |
| US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| EP3201189A1 (en) * | 2014-10-01 | 2017-08-09 | Respivert Limited | N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors |
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| CN109689640B (zh) | 2016-07-08 | 2022-01-04 | 百时美施贵宝公司 | 可用作免疫调节剂的化合物 |
| US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| JP7150745B2 (ja) | 2017-03-27 | 2022-10-11 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤としての置換イソキノリン誘導体 |
-
2017
- 2017-12-19 KR KR1020197020826A patent/KR102599339B1/ko active Active
- 2017-12-19 ES ES17829456T patent/ES2891528T3/es active Active
- 2017-12-19 WO PCT/US2017/067198 patent/WO2018118848A1/en not_active Ceased
- 2017-12-19 EP EP17829456.7A patent/EP3558970B1/en active Active
- 2017-12-19 US US16/471,531 patent/US10882844B2/en active Active
- 2017-12-19 CN CN201780079156.5A patent/CN110072860B/zh active Active
- 2017-12-19 JP JP2019554486A patent/JP7106572B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130165A1 (es) | Compuestos heterocíclicos, composiciones de los mismos y métodos de tratamiento con ellos | |
| JP2015501833A5 (enExample) | ||
| CA2605854A1 (en) | Novel pyridine derivative and pyrimidine derivative (3) | |
| RU2470017C2 (ru) | Производные пиперидина/пиперазина | |
| RU2356891C2 (ru) | Производные пиридинкарбоксамида и их соли для применения в качестве инсектицида | |
| CR20200503A (es) | Inhibidores de cinasa dependientes de ciclina | |
| JP2014506599A5 (enExample) | ||
| RU2012156940A (ru) | Лекарственные средства, индуцирующие апоптоз, для лечения рака и иммунных и аутоиммунных заболеваний | |
| HRP20212000T1 (hr) | Aminotriazolopiridini kao inhibitori kinaze | |
| JP2018520195A5 (enExample) | ||
| JP2019516755A5 (enExample) | ||
| SI3018132T1 (en) | Condensed imidazole derivatives useful as IDO inhibitors | |
| JP2017502940A5 (enExample) | ||
| JP2018534282A5 (enExample) | ||
| SI3022192T1 (en) | Piperidinyl indole derivatives and their use as inhibitors of complementary factor B | |
| JP2015533177A5 (enExample) | ||
| RU2011100786A (ru) | Производные имидазопиридина в качестве ингибиторов рецепторных тирозинкиназ | |
| MX2013004407A (es) | Derivado de piridina y agente medicinal. | |
| RU2008142360A (ru) | Производные амидов и их применение для лечения нарушений, связанных с белком g | |
| JP2021501756A5 (enExample) | ||
| RU2009123930A (ru) | Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4 | |
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| RU2010125220A (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
| RU2011142753A (ru) | Производные никотинамида, способ их получения и применение в терапии в качестве противораковых агентов | |
| JP2014530197A5 (enExample) |